SG11202010645VA - Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders - Google Patents
Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disordersInfo
- Publication number
- SG11202010645VA SG11202010645VA SG11202010645VA SG11202010645VA SG11202010645VA SG 11202010645V A SG11202010645V A SG 11202010645VA SG 11202010645V A SG11202010645V A SG 11202010645VA SG 11202010645V A SG11202010645V A SG 11202010645VA SG 11202010645V A SG11202010645V A SG 11202010645VA
- Authority
- SG
- Singapore
- Prior art keywords
- lentivector
- transduced
- amelioration
- lysosomal storage
- storage disorders
- Prior art date
Links
- 208000015439 Lysosomal storage disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01205—IMP dehydrogenase (1.1.1.205)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862663786P | 2018-04-27 | 2018-04-27 | |
PCT/US2019/029639 WO2019210301A1 (en) | 2018-04-27 | 2019-04-29 | Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202010645VA true SG11202010645VA (en) | 2020-11-27 |
Family
ID=68295811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202010645VA SG11202010645VA (en) | 2018-04-27 | 2019-04-29 | Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210322472A1 (ja) |
EP (2) | EP3784695B1 (ja) |
JP (1) | JP2021522278A (ja) |
KR (1) | KR20210005167A (ja) |
CN (1) | CN112513072A (ja) |
SG (1) | SG11202010645VA (ja) |
WO (1) | WO2019210301A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3174863A1 (en) * | 2020-04-14 | 2021-10-21 | Ana BUJ BELLO | Vectors for the treatment of acid ceramidase deficiency |
WO2024074142A1 (en) * | 2022-10-08 | 2024-04-11 | Lingyi Biotech Co., Ltd. | Polynucleotides for the treatment of disease associated with gcase deficiency |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX362513B (es) * | 2010-03-23 | 2019-01-22 | Intrexon Corp | Vectores que expresan de manera condicional proteinas terapeuticas, celulas hospedadoras que comprenden vectores, y usos de los mismos. |
PL2646044T3 (pl) * | 2010-11-30 | 2020-03-31 | Orphazyme A/S | Sposoby zwiększenia aktywności wewnątrzkomórkowej Hsp70 |
US9387236B2 (en) * | 2011-06-10 | 2016-07-12 | Prothera Inc. | Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases |
AU2012315699B2 (en) * | 2011-09-30 | 2017-08-17 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
DK3086784T3 (da) * | 2013-12-23 | 2019-06-17 | Bcn Peptides Sa | Bicalutamid analoger eller (s)-bicalutamid som exocytose aktiverende forbindelser til brug i behandling af lysosomal lagringssygdom eller glycogenose |
GB201407322D0 (en) * | 2014-04-25 | 2014-06-11 | Ospedale San Raffaele | Gene therapy |
JP6634073B2 (ja) * | 2014-05-14 | 2020-01-22 | エステベ ファーマシューティカルズ, ソシエダッド アノニマEsteve Pharmaceuticals, S.A. | リソソーム蓄積症処置用のアデノ随伴ウイルスベクター |
EP3384012A1 (en) * | 2015-12-04 | 2018-10-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of amplifying a population of antigen-specific memory cd4+ t cells using artificial presenting cells expressing hla class ii molecules |
-
2019
- 2019-04-29 JP JP2020560341A patent/JP2021522278A/ja active Pending
- 2019-04-29 CN CN201980043179.XA patent/CN112513072A/zh active Pending
- 2019-04-29 SG SG11202010645VA patent/SG11202010645VA/en unknown
- 2019-04-29 WO PCT/US2019/029639 patent/WO2019210301A1/en active Application Filing
- 2019-04-29 US US17/050,949 patent/US20210322472A1/en active Pending
- 2019-04-29 EP EP19793684.2A patent/EP3784695B1/en active Active
- 2019-04-29 EP EP23190055.6A patent/EP4285921A3/en active Pending
- 2019-04-29 KR KR1020207034012A patent/KR20210005167A/ko active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
EP3784695A1 (en) | 2021-03-03 |
CN112513072A (zh) | 2021-03-16 |
KR20210005167A (ko) | 2021-01-13 |
EP4285921A3 (en) | 2024-03-06 |
EP4285921A2 (en) | 2023-12-06 |
US20210322472A1 (en) | 2021-10-21 |
JP2021522278A (ja) | 2021-08-30 |
EP3784695B1 (en) | 2023-08-09 |
EP3784695A4 (en) | 2022-02-23 |
WO2019210301A1 (en) | 2019-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2575360B (en) | Expandable sockets for use with portable media players | |
IL249424A0 (en) | nk-92 cells expressing car as cell therapy factors | |
EP3332438B8 (de) | Redox-flow-zelle zur speicherung elektrischer energie und deren verwendung | |
IL251188A0 (en) | Central memory t cells for t cell stress therapy | |
SG10202005898PA (en) | Cell culture medium | |
EP3164390A4 (en) | Electrochemical energy storage devices | |
IL248538B (en) | Vector viruses unrelated to the treatment of lysosomal storage disorders | |
EP3560334A4 (en) | CELL FREEZING MEDIUM FOR CLINICAL USE | |
EP3134409A4 (en) | Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells | |
EP3445451A4 (en) | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL STORAGE DISORDERS AND DISEASES CHARACTERIZED BY LYSOSOMAL DYSFUNCTION | |
EP3569697B8 (en) | Stem cell therapy in endometrial pathologies | |
EP3107142A4 (en) | Battery cell having asymmetric and indented structure | |
GB201715930D0 (en) | Cell Culture Medium | |
EP3145543A4 (en) | Treatment of eosinophil or mast cell related disorders | |
EP3380102A4 (en) | TELOMER EXTENSION AND ANTI-INFLAMMATORY AGENT FOR CELL REGENERATION | |
EP3128003A4 (en) | Medium for stem cell use | |
EP3574088A4 (en) | METHOD FOR INCREASING THE CLOSURE ACTIVITY OF HEMATOPOETIC STEM CELLS | |
SG11202010645VA (en) | Use of lentivector-transduced t-rapa cells for amelioration of lysosomal storage disorders | |
EP3313386A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | |
EP3178318A4 (en) | Composition for promoting storage stability of stem cells | |
IL262553B (en) | Technology for efficient activation of nkt cells | |
SG11202009770TA (en) | Improving cell access procedure | |
SG11202010878QA (en) | Cell culture medium | |
EP3425696A4 (en) | BATTERY CELL COMPARTMENT WITH VOLATILE CORROSION INHIBITOR | |
EP3784794A4 (en) | TREATMENT OF LYSOSOMAL STORAGE DISORDERS |